Stock news: Morphosys AG - Study data brings the next boost

Biotech stocks have not yet been able to mirror the major stock market upswing since October 2022. The reason for this is the parallel rise in interest rates, which makes the refinancing of growth companies extremely expensive. MorphoSys acquired the US biotech company Constellation Pharmaceutical for USD 1.7 billion in 2021. Since this huge step, the share has lost 25% of its value. Now, however, the situation seems to be under control. A look ahead to 2023/2024 gives hope, and the share price may have recently reached a technical bottom. We analyze the current development.

Den vollständigen Artikel lesen ...